Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

NCT04993664 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Administrative reason

Conditions

Acute Coronary Syndrome
Lipoproteinemia
Inflammation
Genetic Polymorphisms

Interventions

DRUG: Pelacarsen (TQJ230)
DRUG: Placebo

Sponsor

University Medical Centre Ljubljana